FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	: 0.5								

	Check this box if no longer subject
\neg	to Section 16. Form 4 or Form 5
_	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* REED JAN STERN					2. Issuer Name and Ticker or Trading Symbol ANGIODYNAMICS INC [ANGO]								(Ch	Relationshi eck all app	,	ng Pers	son(s) to I		
(Last)	(Fi	rst) (N	3. Date of Earliest Transaction (Month/Day/Year) 07/19/2023											er (give title		Other (s			
14 PLAZA DRIVE					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	M N	γ 1	2110											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication														
				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									ended to						
		Table	l - No	n-Deriva	tive S	ecui	rities	Acq	uired,	Dis	posed of	f, or	Ben	eficia	ally Owr	ned			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)				Execution Execut		ution Date,		Transaction Disposed Code (Instr. 5)		ties Acquired (/ I Of (D) (Instr. 3				cially I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A (I	A) or D)	Price	Reported				
Common Stock 07/19/2					2023			A		17,041	1)	Α	\$0	66,818		D			
		Tab	le II -	Derivati (e.g., pu												ed			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) Execution Date, if any			ition Date,	4. Transaction Code (Instr. 8)		5. Numl of Deriv Secu Acqu (A) o Dispo of (D) (Instr	rative rities nired r osed)	6. Date E Expiration (Month/I	on Da			ount of urities erlying vative urity		3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y D o (I	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	or Nun of						

Explanation of Responses:

1. The acquisition of 17,041 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 17,041 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

/s/ Stephen A. Trowbridge, Attorney in Fact

07/21/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.